We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. A 67-year- 
Introduction
Worldwide, primary liver cancer is the fifth most common cause of cancer-related death with more than 500,000 new cases per year (1, 2) . During the last 2 decades, increases of primary liver cancer incidence rates have been reported from Australia, Central Europe, the United Kingdom, Japan, and North America (1, 2) .
Curative treatments, such as resection, liver transplantation, and percutaneous ablation, induce complete responses in a high proportion of patients and are expected to improve survival. However, candidates for the curative treatment are limited. According to a recent study in Japan, only 58% of the newly registered 18,827 patients with hepatocellular carcinoma could receive curative treatment (3) The prognosis of advanced hepatocellular carcinoma is still unsatisfactory, and extrahepatic metastasis is a major independent prognostic factor for patients with hepatocellular carcinoma (3, 4) . The efficacy of systemic chemotherapy for extrahepatic metastasis has been unsatisfactory.
In this report, we describe a Japanese man who developed peritoneal dissemination of hepatocellular carcinoma after hepatectomy, in whom marked tumor regression was found with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
T a b l e 1 . L a b o r a t o r y d a t a a t t h e d i a g n o s i s o f h e p a t o c e l l u l a r c a r c i n o ma a n d a t t h e d i a g n o s i s o f p e r i t o n e a l d i s s e mi n a t i o n
tive course was uneventful, and his serum levels of alphafetoprotein and des-gamma-carboxy prothrombin decreased after surgery (Fig. 2) .
In May 2005, his serum levels of alpha-fetoprotein and des-gamma-carboxy prothrombin increased unexpectedly. Enhanced computed tomography showed no intrahepatic recurrence of hepatocellular carcinoma but peritoneal dissemination (Fig. 3A B) (Fig. 3C, D (9, 10) . However, recently, the effectiveness of combination chemotherapy using oral tegafur/uracil has been reported (11, 12) .
F i g u r e 1 . De mo n s t r a t i o n o f h e p a t o c e l l u l a r c a r c i n o ma b y e n h a n c e d c o mp u t e d t o mo g r a p h y a n d h i s t o l o g i c a l f e a t u r e s o f t h e n o n -t u mo r o u s l e s i o n a n d t u mo r o u s l e s i o n . A: E n h a n c e d c o mp u t e d t o mog r a p h y s h o ws a h e p a t i c ma s s wi t h e a r l y -p h a s e h y p e r a t t e n u a t i o n , me a s u r i n g 8 . 5 × 5 . 4 c m i n t h e p o st e r i o r s e g me n t o f t h e l i v e r ( a r r o w) . B : T h e h e p a t i c ma s s s h o ws l a t e -p h a s e h y p o a t t e n u a t i o n ( a r r o w) . C: Hi s t o l o g i c a l f e a t u r e s o f t h e r e s e c t e d n o n -t u mo r o u s l e s i o n s h o ws c i r r h o s i s ( HE s t a i n , × 2 5 ) . D: Hi s t o l o g i c a l f e a t u r e s o f t h e r e s e c t e d t u mo r o u s l e s i o n s h o ws a mo d e r a t e l y d i f f e r e n t i a t e d h e p a t o c e l l ul a r c a r c i n o ma wi t h a n i n c r e a s e d n u c l e a r -c y t o p l a s m r a t i o a n d n u c l e a r a t y p i a , wh i c h p r o l i f e r a t e d i n a t r a b e c u l a r p a t t e r n ( HE , × 1 0 0 ) .

Tegafur/uracil consists of tegafur and uracil in a 1 : 4 molar ratio. Tegafur is metabolized to 5-fluorouracil in the liver, and uracil potentiates the efficacy of tegafur by inhibiting dihydropyrimidine dehydrogenase activity. Hepatocellular carcinoma is reported to have a relatively high dihydropyrimidine dehydrogenase activity (13). Furthermore, oral tegafur/uracil is facile. Thus, the administration of tegafur/ uracil to patients with hepatocellular carcinoma may be reasonable.
In a recent report from Japan, major extrahepatic metastasis sites are confirmed to be lung, bone, and lymph node (3) . Peritoneal dissemination is rare and usually is a consequence of rupture of the primary tumor (3, 14) . Furthermore, peritoneal dissemination is reported to be a complication of hepatectomy, microwave coagulation therapy, ethanol injection therapy, and percutaneous needle biopsy (15) (16) (17) (18) (19) (20) (21) r d ( b l a c k a r r o w) l a r g e s t l e s i o n s o f p e r i t o n e a l d i s s e mi n a t i o n b e f o r e  t h e c h e mo t h e r a p y , me a s u r i n g 1 . 1 × 1 . 0 c m a n d 1 . 0 × 0 . 8 c m, r e s p e c t i v e l y . t h e r a p y , me a s u r i n g 1 . 6 × 1 . 3 c m ( a r r o w) . 
F i g u r e 3 . De mo n s t r a t i o n o f h e p a t o c e l l u l a r c a r c i n o ma d i s s e mi n a t e d t o t h e p e r i t o n e u m b y c o m p u t e d t o mo g r a p h y b e f o r e a n d a f t e r t h e c h e mo t h e r a p y . A: Co mp u t e d t o mo g r a p h y s h o ws t h e s e c o n d ( wh i t e a r r o w) a n d t h e t h i
B : Co mp u t e d t o mo g r a p h y s h o ws t h e l a r g e s t l e s i o n o f p e r i t o n e a l d i s s e mi n a t i o n b e f o r e t h e c h e mo t h e r a p y , me a s u r i n g 2 . 6 × 2 . 1 c m ( a r r o w) . C: Co mp u t e d t o mo g r a p h y s h o ws c o mp l e t e d i s a p p e a r a n c e o f d i s s e mi n a t e d l e s i o n s a f t e r t h e c h e mo t h e r a p y ( a r r o w) . D: Co mp u t e d t o mo g r a p h y s h o ws a r e d u c e d d i s s e mi n a t e d l e s i o n a f t e r t h e c h e mo
